BeOne Medicines Ltd. (Stock Code: 06160) published statutory and consolidated financial statements for 2025. According to the Swiss statutory statements, which cover May 27, 2025 through December 31, 2025, BeOne Medicines Ltd. reported total assets of US$9.80 billion and total liabilities at US$1.43 billion, resulting in shareholders’ equity of US$8.37 billion. The statutory net loss for that period stood at US$113.90 million.

The consolidated financial statements indicated total revenues of US$5.34 billion for the year, of which US$5.28 billion stemmed from net product sales. Research and development expenses reached US$2.15 billion, while selling, general and administrative expenses totaled US$2.08 billion. Net income was US$286.93 million, marking a significant improvement compared to prior periods.

The announcement included the statutory auditor’s opinions from Ernst & Young AG, which found the financial statements to be in compliance with Swiss law and the Company’s articles of incorporation. The materials also highlighted enhanced governance and reporting details following the entity’s redomiciliation to Switzerland. These disclosures were issued to inform shareholders and the market of BeOne Medicines Ltd.’s latest financial position and performance.